GO
| HSI1 | 25,584.79 | +19.05 | 231.21B |
| HSCEI1 | 8,490.39 | +0.08 | 65.14B |
| Back Zoom + Zoom - Block Traded | |
|
2026-08-28 15:51:07 CICC issued a report saying that WUXI BIO (02269.HK) saw improved profitability, while its project pipeline and complex molecule business continued to expand. Its revenue for the first half of the year was RMB11.787 billion, up 18.4% YoY, or up 23.4% YoY at constant exchange rates. Gross margin rose 3.5 ppts YoY to 46.2%. Net profit increased 4.3% YoY to RMB2.44 billion, while adjusted net profit rose 38.4% YoY to RMB3.306 billion. Adjusted net profit margin increased 4 ppts YoY to 28%. Based on improved operating efficiency, the broker raised its 2026 and 2027 adjusted net profit forecasts for WUXI BIO (02269.HK) by 8% and 9.4% to RMB6.665 billion and RMB7.9 billion, respectively. It maintained an "Outperform" rating. As the average valuation of the H-share pharmaceutical sector has risen recently, the broker raised its TP for WUXI BIO (02269.HK) by 25% to HKD60, corresponding to forecast P/E ratios of 32.2x and 27.1x for the next two years respectively. (da/j)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |